A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma

Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI)‐targeted therapy has emerged as a viable treatment for patients with advanced non‐small cell lung cancer with common EGFR mutations. The uncommon G719X and S768I mutations can co‐occur as complex mutations in the same tumor. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Toshiki, Yamasaki, Kei, Shingu, Tatsuya, Higashi, Yasuyuki, Maeda, Yukinori, Uryu, Takumu, Kubo, Naoto, Kawaguchi, Takako, Nishida, Chinatsu, Yatera, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569900/
https://www.ncbi.nlm.nih.gov/pubmed/37614204
http://dx.doi.org/10.1111/1759-7714.15085

Ejemplares similares

Ejemplares similares